Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained?

Anti-Tumour Necrosis Factor-α Induced Systemic Lupus Erythematosus

Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.

Nontuberculous mycobacterial (NTM) disease and tuberculosis (TB) develop during anti-tumour necrosis factor (TNF)-α therapy. We compared clinical characteristics and outcomes between the two diseases. A total of 1165 patients were screened for TB and treated with TNF-α antagonists from July 2004 to July 2013 for the following conditions: inflammatory bowel disease (n = 422), rheumatoid arthriti...

Anti-Tumour Necrosis Factor-α Therapy in Crohn’s Disease

Crohn’s disease is a chronic, relapsing, inflammatory disease of the gastro-intestinal tract. Manifestations of the disease may be severe, and lead to long-term therapy with a variety of medications and/or surgery. There are two main classifications of the disease, including the relapsing-remitting chronic active variety, and the penetrating or fistulising variety. Tumour necrosis factor-alpha ...

Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies.

OBJECTIVE Anti-TNF-α agents are remarkably effective in the treatment of SpAs. However, 30% of patients withdraw from anti-TNF-α agents yearly because of inadequate efficacy or side effects. The objective of this study was to assess in current practice the response to a second and a third anti-TNF-α. METHODS Retrospectively, all records of patients who had received at least two anti-TNF-α age...

Tumour necrosis factor-α in nasal allergy

Tumour necrosis factor-alpha (TNF-alpha) was measured by enzyme-linked immunosorbent assay and eosinophil cationic protein (ECP) by radio-immunoassay to evaluate TNF-alpha in nasal allergy. There was no significant difference either between the mean concentrations of TNF-alpha in nasal secretions from the patients with perennial nasal allergy and those of normal subjects, or between the TNF-alp...